CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The project focuses on developing a novel therapeutic approach for breast and ovarian cancers with homologous recombination defects. By targeting enzyme X, which is crucial for the survival of these cancer cells, the project aims to create an effective treatment option that overcomes resistance to existing therapies.
Breast and ovarian carcinomas are aggressive tumors with few treatment options and high recurrence rates.
About half of these tumors shows defects in homologous recombination (HR) repair.
Defect in HR (HRD) causes genomic instability and dependence on poly (ADP-ribose) polymerase (PARP)-mediated DNA repair.
As a result, PARP inhibitors (PARPi) are now widely used for the treatment of these tumors.
However, resistance to PARPi is emerging as the major obstacle to clinical effectiveness.
Consequen…
INSTITUT CURIE
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
